Association between oral anticoagulant therapy and in‐hospital complications and mortality
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70087 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Juliana Lagrave und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital del Mar Research Institute, Barcelona, Spain. Hauptthemen laut MEDLINE: Hospital Mortality, Vitamin K, Hemorrhage, Anticoagulants. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, European Union, European Commission.
Abstract (Originalsprache)
Aims
This study aimed to identify patterns of direct oral anticoagulant (DOAC) and vitamin K antagonist (VKA) use in hospitalized patients and to examine their association with in‐hospital haemorrhagic complications and mortality.
Methods
An observational cross‐sectional study was conducted among hospitalized patients ≥18 years from 2018 to 2022. Data on hospital discharges were obtained from the minimum data set and were matched with pharmacy records to identify patients treated with DOACs or VKAs. In‐hospital haemorrhagic complications and mortality rates were calculated for study groups. Multivariate logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (95%CIs), adjusting for age, sex and comorbidities. Analyses were stratified by medical and surgical profiles. Statistical significance was set at .05.
Results
The study included 74 190 patients, with 4774 receiving DOACs and 1768 VKAs. During the study period, DOAC use increased by 45.11%. DOAC‐treated patients had lower complication rates than those treated with VKAs (1.9 vs . 2.8%, respectively; P = .032). DOAC use was linked to a lower risk of haemorrhagic complications in surgical patients (OR = 0.65; 95%CI: 0.35–0.91), while in medical patients, the reduction in risk was not statistically significant (OR = 0.59; 95%CI: 0.33–1.10). No effect on mortality risk was observed among medical and surgical patients.
Conclusions
The increased use of DOACs among hospitalized patients showed a protective effect against haemorrhagic complications in surgical patients, supporting their increasing use in hospital settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital del Mar Research Institute, Barcelona, Spain.
- Department of Epidemiology and Evaluation, Hospital del Mar, Barcelona, Spain.
- RICAPPS. Research Network on Chronicity, Primary Care, and Prevention and Health Promotion, Carlos III Health Institute, Madrid, Spain.
- Medicines Area and Pharmacy Service, Barcelona Territorial Management, Institut Català de la Salut, Barcelona, Spain.
- Department of Hematology, Hospital del Mar, Barcelona, Spain.
- Department of Pharmacy, Hospital del Mar, Barcelona, Spain.
ORCID-Profile: Laia Domingo
Förderung
- Instituto de Salud Carlos III
- European Union
- European Commission
Zitieren
APA
Lagrave, J., Domingo, L., Barceló-Vidal, J., Comas, M., Jimenez, C., Ferrández, O., Castells, X., & Sala, M. (2025). Association between oral anticoagulant therapy and in‐hospital complications and mortality. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70087
Vancouver
Lagrave J, Domingo L, Barceló-Vidal J, Comas M, Jimenez C, Ferrández O, et al. Association between oral anticoagulant therapy and in‐hospital complications and mortality. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70087
BibTeX
@article{Lagrave2025,
author = {Lagrave, Juliana and Domingo, Laia and Barceló-Vidal, Jaime and Comas, Mercè and Jimenez, Carmen and Ferrández, Olivia and Castells, Xavier and Sala, Maria},
title = {Association between oral anticoagulant therapy and in‐hospital complications and mortality},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70087}
}
EUVIMED